Global Solifenacin Succinate Drug Market

Solifenacin Succinate Drug Comprehensive Study by Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Form (Tablet, Suspension), End User (Hospitals, Clinics), Dosage Availability (5 mg, 10 mg) Players and Region - Global Market Outlook to 2028

Solifenacin Succinate Drug Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Solifenacin Succinate Drug Market Overview:
Overactive bladder is a common condition that has an unfavourable effect on the quality of life. The appearance of urgency incontinence confers significant morbidity above and beyond that of OAB sufferers who are continent. The primary treatment for OAB and urgency incontinence is a combination of behavioural measures and antimuscarinic drug therapy. and Solifenacin Succinate Drug is used to treat overactive bladder (a condition in which the bladder muscles contract uncontrollably and cause frequent urination, urgent need to urinate, and inability to control urination). It is used to treat neurogenic detrusor overactivity (a bladder control condition caused by the brain, spinal cord or nerve problem) it works by relaxing the bladder muscles.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Novel Treatments, Robust Pipeline, and Patent Cliff of Certain Drugs

Market Growth Drivers:
Ageing Population and Rising Incidence of Diseases Characterized By OAB

Challenges:
Lack of Awareness regarding the drug

Restraints:
The adverse effect of the solifenacin succinate drug

Opportunities:
New emerging technologies and drug development with expanding health expenditure and infrastructure, rising number of elderly people are some major factor of growth opportunities

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Astellas Pharma, Inc. (Japan), Cadila Healthcare Limited (India), Alembic Pharmaceuticals (India), Teva Pharmaceutical Industries Limited (Israel), Mylan N.V. (United States), Hisamitsu Pharmaceutical Co., Inc. (Japan), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), Cogentix Medical, Inc. (United States), Enantiotech Co. Ltd. (China) and Sun Pharmaceutical Industries(India). Additionally, following companies can also be profiled that are part of our coverage like Hetero Healthcare Limited(India). Analyst at AMA Research see India Players to retain maximum share of Global Solifenacin Succinate Drug market by 2028. Considering Market by Form, the sub-segment i.e. Tablet will boost the Solifenacin Succinate Drug market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Solifenacin Succinate Drug market. Considering Market by Dosage Availability, the sub-segment i.e. 5 mg will boost the Solifenacin Succinate Drug market.

In May 2019 Alembic Pharmaceuticals the Company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Solifenacin Succinate Tablets, 5 mg and 10 mg

What Can be Explored with the Solifenacin Succinate Drug Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Solifenacin Succinate Drug Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Solifenacin Succinate Drug
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Solifenacin Succinate Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Solifenacin Succinate Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Solifenacin Succinate Drug Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Idiopathic Bladder Overactivity
  • Neurogenic Bladder Overactivity
By Form
  • Tablet
  • Suspension

By End User
  • Hospitals
  • Clinics

By Dosage Availability
  • 5 mg
  • 10 mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Ageing Population and Rising Incidence of Diseases Characterized By OAB
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness regarding the drug
    • 3.4. Market Trends
      • 3.4.1. Novel Treatments, Robust Pipeline, and Patent Cliff of Certain Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Solifenacin Succinate Drug, by Type, Form, End User, Dosage Availability and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Solifenacin Succinate Drug (Value)
      • 5.2.1. Global Solifenacin Succinate Drug by: Type (Value)
        • 5.2.1.1. Idiopathic Bladder Overactivity
        • 5.2.1.2. Neurogenic Bladder Overactivity
      • 5.2.2. Global Solifenacin Succinate Drug by: Form (Value)
        • 5.2.2.1. Tablet
        • 5.2.2.2. Suspension
      • 5.2.3. Global Solifenacin Succinate Drug by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
      • 5.2.4. Global Solifenacin Succinate Drug by: Dosage Availability (Value)
        • 5.2.4.1. 5 mg
        • 5.2.4.2. 10 mg
      • 5.2.5. Global Solifenacin Succinate Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Solifenacin Succinate Drug (Volume)
      • 5.3.1. Global Solifenacin Succinate Drug by: Type (Volume)
        • 5.3.1.1. Idiopathic Bladder Overactivity
        • 5.3.1.2. Neurogenic Bladder Overactivity
      • 5.3.2. Global Solifenacin Succinate Drug by: Form (Volume)
        • 5.3.2.1. Tablet
        • 5.3.2.2. Suspension
      • 5.3.3. Global Solifenacin Succinate Drug by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
      • 5.3.4. Global Solifenacin Succinate Drug by: Dosage Availability (Volume)
        • 5.3.4.1. 5 mg
        • 5.3.4.2. 10 mg
      • 5.3.5. Global Solifenacin Succinate Drug Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Solifenacin Succinate Drug (Price)
      • 5.4.1. Global Solifenacin Succinate Drug by: Type (Price)
  • 6. Solifenacin Succinate Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astellas Pharma, Inc. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cadila Healthcare Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Alembic Pharmaceuticals (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries Limited (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan N.V. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hisamitsu Pharmaceutical Co., Inc. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aurobindo Pharma Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Apotex, Inc. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cogentix Medical, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Enantiotech Co. Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sun Pharmaceutical Industries(India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Solifenacin Succinate Drug Sale, by Type, Form, End User, Dosage Availability and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Solifenacin Succinate Drug (Value)
      • 7.2.1. Global Solifenacin Succinate Drug by: Type (Value)
        • 7.2.1.1. Idiopathic Bladder Overactivity
        • 7.2.1.2. Neurogenic Bladder Overactivity
      • 7.2.2. Global Solifenacin Succinate Drug by: Form (Value)
        • 7.2.2.1. Tablet
        • 7.2.2.2. Suspension
      • 7.2.3. Global Solifenacin Succinate Drug by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
      • 7.2.4. Global Solifenacin Succinate Drug by: Dosage Availability (Value)
        • 7.2.4.1. 5 mg
        • 7.2.4.2. 10 mg
      • 7.2.5. Global Solifenacin Succinate Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Solifenacin Succinate Drug (Volume)
      • 7.3.1. Global Solifenacin Succinate Drug by: Type (Volume)
        • 7.3.1.1. Idiopathic Bladder Overactivity
        • 7.3.1.2. Neurogenic Bladder Overactivity
      • 7.3.2. Global Solifenacin Succinate Drug by: Form (Volume)
        • 7.3.2.1. Tablet
        • 7.3.2.2. Suspension
      • 7.3.3. Global Solifenacin Succinate Drug by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
      • 7.3.4. Global Solifenacin Succinate Drug by: Dosage Availability (Volume)
        • 7.3.4.1. 5 mg
        • 7.3.4.2. 10 mg
      • 7.3.5. Global Solifenacin Succinate Drug Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Solifenacin Succinate Drug (Price)
      • 7.4.1. Global Solifenacin Succinate Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Solifenacin Succinate Drug: by Type(USD Million)
  • Table 2. Solifenacin Succinate Drug Idiopathic Bladder Overactivity , by Region USD Million (2017-2022)
  • Table 3. Solifenacin Succinate Drug Neurogenic Bladder Overactivity , by Region USD Million (2017-2022)
  • Table 4. Solifenacin Succinate Drug: by Form(USD Million)
  • Table 5. Solifenacin Succinate Drug Tablet , by Region USD Million (2017-2022)
  • Table 6. Solifenacin Succinate Drug Suspension , by Region USD Million (2017-2022)
  • Table 7. Solifenacin Succinate Drug: by End User(USD Million)
  • Table 8. Solifenacin Succinate Drug Hospitals , by Region USD Million (2017-2022)
  • Table 9. Solifenacin Succinate Drug Clinics , by Region USD Million (2017-2022)
  • Table 10. Solifenacin Succinate Drug: by Dosage Availability(USD Million)
  • Table 11. Solifenacin Succinate Drug 5 mg , by Region USD Million (2017-2022)
  • Table 12. Solifenacin Succinate Drug 10 mg , by Region USD Million (2017-2022)
  • Table 13. South America Solifenacin Succinate Drug, by Country USD Million (2017-2022)
  • Table 14. South America Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 15. South America Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 16. South America Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 17. South America Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 18. Brazil Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 19. Brazil Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 20. Brazil Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 21. Brazil Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 22. Argentina Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 23. Argentina Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 24. Argentina Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 25. Argentina Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 26. Rest of South America Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 27. Rest of South America Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 28. Rest of South America Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 29. Rest of South America Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 30. Asia Pacific Solifenacin Succinate Drug, by Country USD Million (2017-2022)
  • Table 31. Asia Pacific Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 32. Asia Pacific Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 33. Asia Pacific Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 34. Asia Pacific Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 35. China Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 36. China Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 37. China Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 38. China Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 39. Japan Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 40. Japan Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 41. Japan Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 42. Japan Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 43. India Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 44. India Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 45. India Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 46. India Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 47. South Korea Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 48. South Korea Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 49. South Korea Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 50. South Korea Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 51. Taiwan Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 52. Taiwan Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 53. Taiwan Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 54. Taiwan Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 55. Australia Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 56. Australia Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 57. Australia Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 58. Australia Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 59. Rest of Asia-Pacific Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 60. Rest of Asia-Pacific Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 61. Rest of Asia-Pacific Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 63. Europe Solifenacin Succinate Drug, by Country USD Million (2017-2022)
  • Table 64. Europe Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 65. Europe Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 66. Europe Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 67. Europe Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 68. Germany Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 69. Germany Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 70. Germany Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 71. Germany Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 72. France Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 73. France Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 74. France Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 75. France Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 76. Italy Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 77. Italy Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 78. Italy Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 79. Italy Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 80. United Kingdom Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 81. United Kingdom Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 82. United Kingdom Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 83. United Kingdom Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 84. Netherlands Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 85. Netherlands Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 86. Netherlands Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 87. Netherlands Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 88. Rest of Europe Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 89. Rest of Europe Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 90. Rest of Europe Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 91. Rest of Europe Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 92. MEA Solifenacin Succinate Drug, by Country USD Million (2017-2022)
  • Table 93. MEA Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 94. MEA Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 95. MEA Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 96. MEA Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 97. Middle East Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 98. Middle East Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 99. Middle East Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 100. Middle East Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 101. Africa Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 102. Africa Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 103. Africa Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 104. Africa Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 105. North America Solifenacin Succinate Drug, by Country USD Million (2017-2022)
  • Table 106. North America Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 107. North America Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 108. North America Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 109. North America Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 110. United States Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 111. United States Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 112. United States Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 113. United States Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 114. Canada Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 115. Canada Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 116. Canada Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 117. Canada Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 118. Mexico Solifenacin Succinate Drug, by Type USD Million (2017-2022)
  • Table 119. Mexico Solifenacin Succinate Drug, by Form USD Million (2017-2022)
  • Table 120. Mexico Solifenacin Succinate Drug, by End User USD Million (2017-2022)
  • Table 121. Mexico Solifenacin Succinate Drug, by Dosage Availability USD Million (2017-2022)
  • Table 122. Solifenacin Succinate Drug Sales: by Type(K Tons)
  • Table 123. Solifenacin Succinate Drug Sales Idiopathic Bladder Overactivity , by Region K Tons (2017-2022)
  • Table 124. Solifenacin Succinate Drug Sales Neurogenic Bladder Overactivity , by Region K Tons (2017-2022)
  • Table 125. Solifenacin Succinate Drug Sales: by Form(K Tons)
  • Table 126. Solifenacin Succinate Drug Sales Tablet , by Region K Tons (2017-2022)
  • Table 127. Solifenacin Succinate Drug Sales Suspension , by Region K Tons (2017-2022)
  • Table 128. Solifenacin Succinate Drug Sales: by End User(K Tons)
  • Table 129. Solifenacin Succinate Drug Sales Hospitals , by Region K Tons (2017-2022)
  • Table 130. Solifenacin Succinate Drug Sales Clinics , by Region K Tons (2017-2022)
  • Table 131. Solifenacin Succinate Drug Sales: by Dosage Availability(K Tons)
  • Table 132. Solifenacin Succinate Drug Sales 5 mg , by Region K Tons (2017-2022)
  • Table 133. Solifenacin Succinate Drug Sales 10 mg , by Region K Tons (2017-2022)
  • Table 134. South America Solifenacin Succinate Drug Sales, by Country K Tons (2017-2022)
  • Table 135. South America Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 136. South America Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 137. South America Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 138. South America Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 139. Brazil Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 140. Brazil Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 141. Brazil Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 142. Brazil Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 143. Argentina Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 144. Argentina Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 145. Argentina Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 146. Argentina Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 147. Rest of South America Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 148. Rest of South America Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 149. Rest of South America Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 150. Rest of South America Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 151. Asia Pacific Solifenacin Succinate Drug Sales, by Country K Tons (2017-2022)
  • Table 152. Asia Pacific Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 153. Asia Pacific Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 154. Asia Pacific Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 155. Asia Pacific Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 156. China Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 157. China Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 158. China Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 159. China Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 160. Japan Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 161. Japan Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 162. Japan Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 163. Japan Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 164. India Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 165. India Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 166. India Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 167. India Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 168. South Korea Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 169. South Korea Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 170. South Korea Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 171. South Korea Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 172. Taiwan Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 173. Taiwan Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 174. Taiwan Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 175. Taiwan Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 176. Australia Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 177. Australia Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 178. Australia Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 179. Australia Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 180. Rest of Asia-Pacific Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 181. Rest of Asia-Pacific Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 182. Rest of Asia-Pacific Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 183. Rest of Asia-Pacific Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 184. Europe Solifenacin Succinate Drug Sales, by Country K Tons (2017-2022)
  • Table 185. Europe Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 186. Europe Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 187. Europe Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 188. Europe Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 189. Germany Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 190. Germany Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 191. Germany Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 192. Germany Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 193. France Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 194. France Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 195. France Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 196. France Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 197. Italy Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 198. Italy Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 199. Italy Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 200. Italy Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 201. United Kingdom Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 202. United Kingdom Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 203. United Kingdom Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 204. United Kingdom Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 205. Netherlands Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 206. Netherlands Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 207. Netherlands Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 208. Netherlands Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 209. Rest of Europe Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 210. Rest of Europe Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 211. Rest of Europe Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 212. Rest of Europe Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 213. MEA Solifenacin Succinate Drug Sales, by Country K Tons (2017-2022)
  • Table 214. MEA Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 215. MEA Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 216. MEA Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 217. MEA Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 218. Middle East Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 219. Middle East Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 220. Middle East Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 221. Middle East Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 222. Africa Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 223. Africa Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 224. Africa Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 225. Africa Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 226. North America Solifenacin Succinate Drug Sales, by Country K Tons (2017-2022)
  • Table 227. North America Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 228. North America Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 229. North America Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 230. North America Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 231. United States Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 232. United States Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 233. United States Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 234. United States Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 235. Canada Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 236. Canada Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 237. Canada Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 238. Canada Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 239. Mexico Solifenacin Succinate Drug Sales, by Type K Tons (2017-2022)
  • Table 240. Mexico Solifenacin Succinate Drug Sales, by Form K Tons (2017-2022)
  • Table 241. Mexico Solifenacin Succinate Drug Sales, by End User K Tons (2017-2022)
  • Table 242. Mexico Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2017-2022)
  • Table 243. Solifenacin Succinate Drug: by Type(USD/Units)
  • Table 244. Company Basic Information, Sales Area and Its Competitors
  • Table 245. Company Basic Information, Sales Area and Its Competitors
  • Table 246. Company Basic Information, Sales Area and Its Competitors
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Solifenacin Succinate Drug: by Type(USD Million)
  • Table 256. Solifenacin Succinate Drug Idiopathic Bladder Overactivity , by Region USD Million (2023-2028)
  • Table 257. Solifenacin Succinate Drug Neurogenic Bladder Overactivity , by Region USD Million (2023-2028)
  • Table 258. Solifenacin Succinate Drug: by Form(USD Million)
  • Table 259. Solifenacin Succinate Drug Tablet , by Region USD Million (2023-2028)
  • Table 260. Solifenacin Succinate Drug Suspension , by Region USD Million (2023-2028)
  • Table 261. Solifenacin Succinate Drug: by End User(USD Million)
  • Table 262. Solifenacin Succinate Drug Hospitals , by Region USD Million (2023-2028)
  • Table 263. Solifenacin Succinate Drug Clinics , by Region USD Million (2023-2028)
  • Table 264. Solifenacin Succinate Drug: by Dosage Availability(USD Million)
  • Table 265. Solifenacin Succinate Drug 5 mg , by Region USD Million (2023-2028)
  • Table 266. Solifenacin Succinate Drug 10 mg , by Region USD Million (2023-2028)
  • Table 267. South America Solifenacin Succinate Drug, by Country USD Million (2023-2028)
  • Table 268. South America Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 269. South America Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 270. South America Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 271. South America Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 272. Brazil Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 273. Brazil Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 274. Brazil Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 275. Brazil Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 276. Argentina Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 277. Argentina Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 278. Argentina Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 279. Argentina Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 280. Rest of South America Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 281. Rest of South America Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 282. Rest of South America Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 283. Rest of South America Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 284. Asia Pacific Solifenacin Succinate Drug, by Country USD Million (2023-2028)
  • Table 285. Asia Pacific Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 286. Asia Pacific Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 287. Asia Pacific Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 288. Asia Pacific Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 289. China Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 290. China Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 291. China Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 292. China Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 293. Japan Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 294. Japan Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 295. Japan Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 296. Japan Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 297. India Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 298. India Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 299. India Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 300. India Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 301. South Korea Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 302. South Korea Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 303. South Korea Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 304. South Korea Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 305. Taiwan Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 306. Taiwan Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 307. Taiwan Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 308. Taiwan Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 309. Australia Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 310. Australia Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 311. Australia Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 312. Australia Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 313. Rest of Asia-Pacific Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 314. Rest of Asia-Pacific Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 315. Rest of Asia-Pacific Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 316. Rest of Asia-Pacific Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 317. Europe Solifenacin Succinate Drug, by Country USD Million (2023-2028)
  • Table 318. Europe Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 319. Europe Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 320. Europe Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 321. Europe Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 322. Germany Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 323. Germany Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 324. Germany Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 325. Germany Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 326. France Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 327. France Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 328. France Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 329. France Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 330. Italy Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 331. Italy Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 332. Italy Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 333. Italy Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 334. United Kingdom Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 335. United Kingdom Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 336. United Kingdom Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 337. United Kingdom Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 338. Netherlands Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 339. Netherlands Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 340. Netherlands Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 341. Netherlands Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 342. Rest of Europe Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 343. Rest of Europe Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 344. Rest of Europe Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 345. Rest of Europe Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 346. MEA Solifenacin Succinate Drug, by Country USD Million (2023-2028)
  • Table 347. MEA Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 348. MEA Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 349. MEA Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 350. MEA Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 351. Middle East Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 352. Middle East Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 353. Middle East Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 354. Middle East Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 355. Africa Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 356. Africa Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 357. Africa Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 358. Africa Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 359. North America Solifenacin Succinate Drug, by Country USD Million (2023-2028)
  • Table 360. North America Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 361. North America Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 362. North America Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 363. North America Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 364. United States Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 365. United States Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 366. United States Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 367. United States Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 368. Canada Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 369. Canada Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 370. Canada Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 371. Canada Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 372. Mexico Solifenacin Succinate Drug, by Type USD Million (2023-2028)
  • Table 373. Mexico Solifenacin Succinate Drug, by Form USD Million (2023-2028)
  • Table 374. Mexico Solifenacin Succinate Drug, by End User USD Million (2023-2028)
  • Table 375. Mexico Solifenacin Succinate Drug, by Dosage Availability USD Million (2023-2028)
  • Table 376. Solifenacin Succinate Drug Sales: by Type(K Tons)
  • Table 377. Solifenacin Succinate Drug Sales Idiopathic Bladder Overactivity , by Region K Tons (2023-2028)
  • Table 378. Solifenacin Succinate Drug Sales Neurogenic Bladder Overactivity , by Region K Tons (2023-2028)
  • Table 379. Solifenacin Succinate Drug Sales: by Form(K Tons)
  • Table 380. Solifenacin Succinate Drug Sales Tablet , by Region K Tons (2023-2028)
  • Table 381. Solifenacin Succinate Drug Sales Suspension , by Region K Tons (2023-2028)
  • Table 382. Solifenacin Succinate Drug Sales: by End User(K Tons)
  • Table 383. Solifenacin Succinate Drug Sales Hospitals , by Region K Tons (2023-2028)
  • Table 384. Solifenacin Succinate Drug Sales Clinics , by Region K Tons (2023-2028)
  • Table 385. Solifenacin Succinate Drug Sales: by Dosage Availability(K Tons)
  • Table 386. Solifenacin Succinate Drug Sales 5 mg , by Region K Tons (2023-2028)
  • Table 387. Solifenacin Succinate Drug Sales 10 mg , by Region K Tons (2023-2028)
  • Table 388. South America Solifenacin Succinate Drug Sales, by Country K Tons (2023-2028)
  • Table 389. South America Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 390. South America Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 391. South America Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 392. South America Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 393. Brazil Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 394. Brazil Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 395. Brazil Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 396. Brazil Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 397. Argentina Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 398. Argentina Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 399. Argentina Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 400. Argentina Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 401. Rest of South America Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 402. Rest of South America Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 403. Rest of South America Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 404. Rest of South America Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 405. Asia Pacific Solifenacin Succinate Drug Sales, by Country K Tons (2023-2028)
  • Table 406. Asia Pacific Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 407. Asia Pacific Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 408. Asia Pacific Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 409. Asia Pacific Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 410. China Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 411. China Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 412. China Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 413. China Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 414. Japan Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 415. Japan Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 416. Japan Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 417. Japan Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 418. India Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 419. India Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 420. India Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 421. India Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 422. South Korea Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 423. South Korea Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 424. South Korea Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 425. South Korea Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 426. Taiwan Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 427. Taiwan Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 428. Taiwan Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 429. Taiwan Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 430. Australia Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 431. Australia Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 432. Australia Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 433. Australia Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 434. Rest of Asia-Pacific Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 435. Rest of Asia-Pacific Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 436. Rest of Asia-Pacific Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 437. Rest of Asia-Pacific Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 438. Europe Solifenacin Succinate Drug Sales, by Country K Tons (2023-2028)
  • Table 439. Europe Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 440. Europe Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 441. Europe Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 442. Europe Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 443. Germany Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 444. Germany Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 445. Germany Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 446. Germany Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 447. France Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 448. France Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 449. France Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 450. France Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 451. Italy Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 452. Italy Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 453. Italy Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 454. Italy Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 455. United Kingdom Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 456. United Kingdom Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 457. United Kingdom Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 458. United Kingdom Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 459. Netherlands Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 460. Netherlands Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 461. Netherlands Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 462. Netherlands Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 463. Rest of Europe Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 464. Rest of Europe Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 465. Rest of Europe Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 466. Rest of Europe Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 467. MEA Solifenacin Succinate Drug Sales, by Country K Tons (2023-2028)
  • Table 468. MEA Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 469. MEA Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 470. MEA Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 471. MEA Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 472. Middle East Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 473. Middle East Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 474. Middle East Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 475. Middle East Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 476. Africa Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 477. Africa Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 478. Africa Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 479. Africa Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 480. North America Solifenacin Succinate Drug Sales, by Country K Tons (2023-2028)
  • Table 481. North America Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 482. North America Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 483. North America Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 484. North America Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 485. United States Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 486. United States Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 487. United States Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 488. United States Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 489. Canada Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 490. Canada Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 491. Canada Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 492. Canada Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 493. Mexico Solifenacin Succinate Drug Sales, by Type K Tons (2023-2028)
  • Table 494. Mexico Solifenacin Succinate Drug Sales, by Form K Tons (2023-2028)
  • Table 495. Mexico Solifenacin Succinate Drug Sales, by End User K Tons (2023-2028)
  • Table 496. Mexico Solifenacin Succinate Drug Sales, by Dosage Availability K Tons (2023-2028)
  • Table 497. Solifenacin Succinate Drug: by Type(USD/Units)
  • Table 498. Research Programs/Design for This Report
  • Table 499. Key Data Information from Secondary Sources
  • Table 500. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Solifenacin Succinate Drug: by Type USD Million (2017-2022)
  • Figure 5. Global Solifenacin Succinate Drug: by Form USD Million (2017-2022)
  • Figure 6. Global Solifenacin Succinate Drug: by End User USD Million (2017-2022)
  • Figure 7. Global Solifenacin Succinate Drug: by Dosage Availability USD Million (2017-2022)
  • Figure 8. South America Solifenacin Succinate Drug Share (%), by Country
  • Figure 9. Asia Pacific Solifenacin Succinate Drug Share (%), by Country
  • Figure 10. Europe Solifenacin Succinate Drug Share (%), by Country
  • Figure 11. MEA Solifenacin Succinate Drug Share (%), by Country
  • Figure 12. North America Solifenacin Succinate Drug Share (%), by Country
  • Figure 13. Global Solifenacin Succinate Drug: by Type K Tons (2017-2022)
  • Figure 14. Global Solifenacin Succinate Drug: by Form K Tons (2017-2022)
  • Figure 15. Global Solifenacin Succinate Drug: by End User K Tons (2017-2022)
  • Figure 16. Global Solifenacin Succinate Drug: by Dosage Availability K Tons (2017-2022)
  • Figure 17. South America Solifenacin Succinate Drug Share (%), by Country
  • Figure 18. Asia Pacific Solifenacin Succinate Drug Share (%), by Country
  • Figure 19. Europe Solifenacin Succinate Drug Share (%), by Country
  • Figure 20. MEA Solifenacin Succinate Drug Share (%), by Country
  • Figure 21. North America Solifenacin Succinate Drug Share (%), by Country
  • Figure 22. Global Solifenacin Succinate Drug: by Type USD/Units (2017-2022)
  • Figure 23. Global Solifenacin Succinate Drug share by Players 2022 (%)
  • Figure 24. Global Solifenacin Succinate Drug share by Players (Top 3) 2022(%)
  • Figure 25. Global Solifenacin Succinate Drug share by Players (Top 5) 2022(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2022
  • Figure 29. Cadila Healthcare Limited (India) Revenue, Net Income and Gross profit
  • Figure 30. Cadila Healthcare Limited (India) Revenue: by Geography 2022
  • Figure 31. Alembic Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 32. Alembic Pharmaceuticals (India) Revenue: by Geography 2022
  • Figure 33. Teva Pharmaceutical Industries Limited (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries Limited (Israel) Revenue: by Geography 2022
  • Figure 35. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Mylan N.V. (United States) Revenue: by Geography 2022
  • Figure 37. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue: by Geography 2022
  • Figure 39. Aurobindo Pharma Limited (India) Revenue, Net Income and Gross profit
  • Figure 40. Aurobindo Pharma Limited (India) Revenue: by Geography 2022
  • Figure 41. Apotex, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 42. Apotex, Inc. (Canada) Revenue: by Geography 2022
  • Figure 43. Cogentix Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Cogentix Medical, Inc. (United States) Revenue: by Geography 2022
  • Figure 45. Enantiotech Co. Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 46. Enantiotech Co. Ltd. (China) Revenue: by Geography 2022
  • Figure 47. Sun Pharmaceutical Industries(India) Revenue, Net Income and Gross profit
  • Figure 48. Sun Pharmaceutical Industries(India) Revenue: by Geography 2022
  • Figure 49. Global Solifenacin Succinate Drug: by Type USD Million (2023-2028)
  • Figure 50. Global Solifenacin Succinate Drug: by Form USD Million (2023-2028)
  • Figure 51. Global Solifenacin Succinate Drug: by End User USD Million (2023-2028)
  • Figure 52. Global Solifenacin Succinate Drug: by Dosage Availability USD Million (2023-2028)
  • Figure 53. South America Solifenacin Succinate Drug Share (%), by Country
  • Figure 54. Asia Pacific Solifenacin Succinate Drug Share (%), by Country
  • Figure 55. Europe Solifenacin Succinate Drug Share (%), by Country
  • Figure 56. MEA Solifenacin Succinate Drug Share (%), by Country
  • Figure 57. North America Solifenacin Succinate Drug Share (%), by Country
  • Figure 58. Global Solifenacin Succinate Drug: by Type K Tons (2023-2028)
  • Figure 59. Global Solifenacin Succinate Drug: by Form K Tons (2023-2028)
  • Figure 60. Global Solifenacin Succinate Drug: by End User K Tons (2023-2028)
  • Figure 61. Global Solifenacin Succinate Drug: by Dosage Availability K Tons (2023-2028)
  • Figure 62. South America Solifenacin Succinate Drug Share (%), by Country
  • Figure 63. Asia Pacific Solifenacin Succinate Drug Share (%), by Country
  • Figure 64. Europe Solifenacin Succinate Drug Share (%), by Country
  • Figure 65. MEA Solifenacin Succinate Drug Share (%), by Country
  • Figure 66. North America Solifenacin Succinate Drug Share (%), by Country
  • Figure 67. Global Solifenacin Succinate Drug: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Astellas Pharma, Inc. (Japan)
  • Cadila Healthcare Limited (India)
  • Alembic Pharmaceuticals (India)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Mylan N.V. (United States)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Aurobindo Pharma Limited (India)
  • Apotex, Inc. (Canada)
  • Cogentix Medical, Inc. (United States)
  • Enantiotech Co. Ltd. (China)
  • Sun Pharmaceutical Industries(India)
Additional players considered in the study are as follows:
Hetero Healthcare Limited(India)
Select User Access Type

Key Highlights of Report


Jul 2023 221 Pages 80 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Solifenacin Succinate Drug Market Quantitative research analysis
Global Solifenacin Succinate Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Solifenacin Succinate Drug market are Astellas Pharma, Inc. (Japan), Cadila Healthcare Limited (India), Alembic Pharmaceuticals (India), Teva Pharmaceutical Industries Limited (Israel), Mylan N.V. (United States), Hisamitsu Pharmaceutical Co., Inc. (Japan), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), Cogentix Medical, Inc. (United States), Enantiotech Co. Ltd. (China) and Sun Pharmaceutical Industries(India), to name a few.
"Novel Treatments, Robust Pipeline, and Patent Cliff of Certain Drugs" is seen as one of major influencing trends for Solifenacin Succinate Drug Market during projected period 2022-2028.
Idiopathic Bladder Overactivity segment in Global market to hold robust market share owing to "Ageing Population and Rising Incidence of Diseases Characterized By OAB".

Know More About Global Solifenacin Succinate Drug Market Report?

Have a Query? Click Here

Other Related Reports

Zolmitriptan Comprehensive Study by Type (Nasal Spray, Orally Disintegrating Tablets, Tablets, Others), Patient Age (Children (below 12 years), Adult), Dosage (2.5 mg, 5 mg), Distribution (Hospital ...
$ 3350
Antiprotozoal drugs Comprehensive Study by Type (Chloroquine, Pyrimethamine, Mefloquine, Hydroxychloroquine, Metronidazole, Atovaquone, Others), Application (Healthcare and Hospital, Others), Form (L...
$ 3350
Pediatrics Respiratory Drugs Comprehensive Study by Disease Type (Asthma, Cystic Fibrosis, Bronchiolitis, Pneumonia, Tuberculosis, Others), Distribution Channel (Hospitals & Clinics, Retail Pharmacie...
$ 3750
Suplatast Tosilate Comprehensive Study by Type (Antiasthmatic agent, Antiallergic agent), Application (Hospitals, Cancer Research Centers, Clinics), Modility (Research, Commercialized), Distribution ...
$ 3350
Postpartum Bleeding Drug Comprehensive Study by Type (Oxytocin, Methergine, Hemabate, Misoprostol, Carboprost, Tranexamic acid, Others), End-user (Hospitals, Maternity Clinics, Out-of-hospital emerge...
$ 3450
Amitriptyline Comprehensive Study by Application (Depression, Migraine, Insomnia, Rheumatic diseases), Form (Tablet, Liquid), Distribution (Online Pharmacy, Hospital Pharmacy, Generic Drug Store), D...
$ 3350